{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:08:53Z","timestamp":1775034533324,"version":"3.50.1"},"reference-count":22,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>To assess the 30-month outcome of treat and extend (TAE) intravitreal ziv-aflibercept therapy in eyes with macular diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this prospective study, consecutive subjects received intravitreal 0.05\u2009mL ziv-aflibercept (1.25\u2009mg) injections for various macular diseases. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution) and central macular thickness (CMT) on spectral domain optical coherence tomography. Paired comparison was done using Wilcoxon signed-rank test calculator.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty-three eyes of 48 subjects (33 na\u00efve eyes) received intravitreal ziv-aflibercept and were followed between 12 and 30 months following TAE included neovascular age-related macular degeneration (nAMD) (35 eyes) and diabetic macular oedema (DMO) (18 eyes). In eyes with nAMD, CMT decreased by 107.8\u2009\u00b5m at the 30-month follow-up (p=0.012) with BCVA gain of 0.52 (p=0.001). In eyes with DMO, CMT decreased by 224.3\u2009\u00b5m at the 30-month follow-up (p=0.027) with BCVA gain of 0.46 (p=0.042). Combining all disease categories, the mean number of injections was 9.2 at month 12, 2.5 between 12 and 18 months, 1.6 between 18 and 24 months and 1.0 between 24 and 30 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Using TAE regimen, intravitreal ziv-aflibercept appeared efficacious at managing retinal disease through month 30 using the TAE regimen.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjophthalmol-2018-312593","type":"journal-article","created":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T16:15:27Z","timestamp":1533226527000},"page":"938-941","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Long-term outcome of treat and extend intravitreal ziv-aflibercept therapy"],"prefix":"10.1136","volume":"103","author":[{"given":"Ahmad M","family":"Mansour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrazzak","family":"Charbaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel Eid","family":"Farah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana A","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Chhablani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,8,2]]},"reference":[{"key":"2020050713041975000_103.7.938.1","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1097\/IAE.0000000000000627","article-title":"Treat-and-extend regimens with anti-VEGF agents in retinal diseases: A literature review and consensus recommendations","volume":"35","author":"Freund","year":"2015","journal-title":"Retina"},{"key":"2020050713041975000_103.7.938.2","doi-asserted-by":"crossref","unstructured":"de Oliveira Dias JR , Costa de Andrade G , Kniggendorf VF , et al . Intravitreal ziv-aflibercept for neovascular age-related macular degeneration: 52-week results. Retina 2017:1. Ahead of Print doi.doi:10.1097\/IAE.0000000000002001","DOI":"10.1097\/IAE.0000000000002001"},{"key":"2020050713041975000_103.7.938.3","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-308319"},{"key":"2020050713041975000_103.7.938.4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ajoc.2017.10.011","article-title":"One-year outcomes of ziv-aflibercept for macular edema in central retinal vein occlusion","volume":"8","author":"Eldeeb","year":"2017","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2020050713041975000_103.7.938.5","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-309994"},{"key":"2020050713041975000_103.7.938.6","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1097\/IAE.0000000000001385","article-title":"Clinical and electrophysiological evaluation after intravitreal ziv-aflibercept for exudative age-related macular degeneration","volume":"37","author":"de Oliveira Dias","year":"2017","journal-title":"Retina"},{"key":"2020050713041975000_103.7.938.7","doi-asserted-by":"crossref","unstructured":"Mansour AM , Ashraf M , Charbaji A , et al . Two-year outcomes of intravitreal ziv-aflibercept. Br J Ophthalmol 2018 Jan 9:bjophthalmol-2017-311591.doi:10.1136\/bjophthalmol-2017-311591","DOI":"10.1136\/bjophthalmol-2017-311591"},{"key":"2020050713041975000_103.7.938.8","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.oret.2016.12.004","article-title":"Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the TREX-AMD study","volume":"1","author":"Wykoff","year":"2017","journal-title":"Ophthalmology Retina"},{"key":"2020050713041975000_103.7.938.9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ajo.2017.06.002","article-title":"Treat-and-extend therapy using aflibercept for neovascular age-related macular degeneration: A prospective clinical trial","volume":"180","author":"DeCroos","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"2020050713041975000_103.7.938.10","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/aos.13480","article-title":"Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol","volume":"95","author":"J\u00f8rstad","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"2020050713041975000_103.7.938.11","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000134"},{"key":"2020050713041975000_103.7.938.12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ophtha.2015.09.018","article-title":"Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the lucentis compared to avastin study treat-and-extend protocol: two-year results","volume":"123","author":"Berg","year":"2016","journal-title":"Ophthalmology"},{"key":"2020050713041975000_103.7.938.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102673"},{"key":"2020050713041975000_103.7.938.14","doi-asserted-by":"crossref","first-page":"e803","DOI":"10.1111\/aos.13352","article-title":"Comparison between the short-term outcomes of bevacizumab and ziv-aflibercept in the treatment of primary diabetic macular oedema","volume":"95","author":"Ashraf","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"2020050713041975000_103.7.938.15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.oret.2016.08.007","article-title":"Two doses of intravitreal ziv-aflibercept versus bevacizumab in treatment of diabetic macular edema: a three-armed, double-blind randomized trial","volume":"1","author":"Baghi","year":"2017","journal-title":"Ophthalmol Retina"},{"key":"2020050713041975000_103.7.938.16","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1097\/IAE.0000000000001000","article-title":"Intravitreal injections of ziv-aflibercept for diabetic macular edema: a pilot study","volume":"36","author":"Andrade","year":"2016","journal-title":"Retina"},{"key":"2020050713041975000_103.7.938.17","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-308679"},{"key":"2020050713041975000_103.7.938.18","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-307249"},{"key":"2020050713041975000_103.7.938.19","doi-asserted-by":"crossref","unstructured":"Hanemoto T , Hikichi Y , Kikuchi N , et al . The impact of different anti-vascular endothelial growth factor treatment regimens on reducing burden for caregivers and patients with wet age-related macular degeneration in a single-center real-world Japanese setting. PLoS One 2017;12:e0189035.doi:10.1371\/journal.pone.0189035","DOI":"10.1371\/journal.pone.0189035"},{"key":"2020050713041975000_103.7.938.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.08.011"},{"key":"2020050713041975000_103.7.938.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"2020050713041975000_103.7.938.22","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1111\/aos.13607","article-title":"Treat-and-extend versus every-other-month regimens with aflibercept in age-related macular degeneration","volume":"96","author":"Haga","year":"2018","journal-title":"Acta Ophthalmol"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2018-312593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:58:19Z","timestamp":1601110699000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2018-312593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,2]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,6,21]]},"published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1136\/bjophthalmol-2018-312593"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2018-312593","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,2]]}}}